# PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

> **NCT05162053** · PHASE1 · COMPLETED · sponsor: **Jiangsu vcare pharmaceutical technology co., LTD** · enrollment: 128 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** vicagrel Capsules
- **DRUG:** Clopidogrel Tablets

## Key facts

- **NCT ID:** NCT05162053
- **Lead sponsor:** Jiangsu vcare pharmaceutical technology co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-09
- **Primary completion:** 2022-11-03
- **Final completion:** 2022-11-03
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162053, "PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05162053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*